The aim of vision screening is to identify amblyopia (lazy eye) and vision loss. Identifying vision problems as early possible is important because undetected vision problems can reduce school achievement, harm the development of hand-eye coordination and lead to a lifelong reduction in vision.
Many countries have local and national vision screening programmes for pre-school children around the age of 5. In the US vision screening is also undertaken by General Practice Paediatrician's.
Objective Acuity ("OAL") is developing the first objective vision screening test based on visual acuity for children under the age of 5.
Currently, vision disorders is the most prevalent, disabling condition among children.
More specifically, amblyopia (lazy eye) is the main cause of preventable vision loss in children.
Studies suggest that a child cannot fully understand, and therefore cannot effectively undertake, a visual acuity test until they are 5 or 6 years old. However, if a child waits until this age, or later, then amblyopia and other vision impairments are significantly harder to treat and related learning difficulties can develop.
Regular vision screening assessments in early childhood reduce this risk by more than 50%. However, inefficiencies in current testing methods limit a child's access to accurate screening and subsequent treatment.
Traditional letter and picture charts are the current gold standard of visual acuity testing in children. However, these charts are subjective, require a response from the participant, and are therefore unreliable, inefficient and inaccurate.
In comparison, current vision screening methods such as portable autorefractors and photo screeners are objective. Nevertheless, these only measure risk factors of children’s vision and not visual acuity making them less effective.
Optokinetic nystagmus (OKN) is an involuntary reflex of the eyes that occurs when an individual sees a moving object or pattern. It is well-recognized as a method of assessing visual acuity, but has, to-date, always been a highly subjective process for the detection of gross visual problems. Optokinetic nystagmus is the basis of our new approach to measuring visual acuity.
Objective Acuity has completed several multinational clinical studies in Adults and Children with a prototype system. These clearly demonstrate proof of concept that the Objective Acuity Vision Screening Test reliably measures visual acuity in a vision screening application. The studies in children's demonstrated a high level of agreement between the Objective Acuity children's test currently considered the global clinical trials gold standard electronic (HOTV) and Lea Symbols visual acuity tests.
The recent studies on a tablet have also demonstrated a very high level of agreement with gold standard electronic (HOTV) and Lea Symbols visual acuity tests, while identifying those children that have vision problems with high sensitivity.
A study of 200 children in the USA with the commercial real-time tablet version of our vision screening test is planned to be initiated in March this year.
Objective Acuity is prosecuting a number of families of patents globally covering the Objective Acuity Vision Screening Test.
We are experienced and diversified in our strength but together we found a sound team.
With extensive experience in research, development and commercialisation we are dedicated to ensure that this exciting innovation gets taken to market.
Adam has over 13 years’ experience in commercialisation, start-up formation and capital raising of medical and health technologies. Adam has had experience in technology commercialisation, attracting foreign direct investment into New Zealand, strategic development and trade promotion. Adam has been involved in business planning, R&D planning raising seed/venture capital and several licensing deals.
A seasoned CFO, Craig has a proven track record of growing companies and increasing shareholder returns. His experience has been focussed on high tech, fast growth companies, with intellectual property and a unique selling proposition, enabling and navigating companies through start-up and high growth periods. He has worked across a broad range of Bio-tech companies as CFO and / or Company Director. Craig has raise over $140m in funds with start-up companies.
Ben is a Professor with joint appointments at The University of Auckland, McGill University and University of Waterloo. He brings significant expertise in vision science and in particular the translation of basic science findings to clinical applications.
Mehrdad has over 10 years of research experience in computer vision, signal processing, and machine learning. Mehrdad received his PhD in Bioengineering from the University of Auckland. Mehrdad provides project leadership and is involved in advanced technology development.
Jason is a senior research fellow at Auckland Bioengineering Institute. He brings significant expertise in development of engineering based methods for use in vision related applications, which has centered to date on simulation of light transport in the eye, measurement of the corneal surface, and image processing techniques for clinical diagnostics.
Boaz is a designer at heart and always find new developments exciting and relish the challenge to find innovative solutions to problems. He believes that sound architectural design is crucial to the success of any product/system, and therefore the opportunity to be part of a new product development from the start appeals to him.
Greg has a distinguished business career spanning more than 40 years. His roles have primarily been in venture investment, executive management, sales and business development, and corporate and professional governance. He has held posts on a number of key industry forums and received many international business awards. Greg has a passion for assisting and investing in disruptive technologies that address some of the world’s major challenges.
Vignesh is an accomplished technology and engineering professional with experience in global technology design, manufacturing, and operations strategy across North America, East Asia, and Asia Pacific. His experience includes engineering management and hardware acquisitions at Apple; product design at Fisher & Paykel Healthcare; and more recently, investment in early stage companies.
Jim Mervis is a catalyst for success in company development in life sciences and communications. He has an extensive background in securities and commercial transactions, defining and establishing strategic alliances and securing the financial and human resources for corporate growth. Over the last decade, Mr. Mervis played a pivotal role in the structure, finance and management of four of the most notable bio-pharmaceutical start-ups of the period.
Director, Crystal Charity Ball Paediatric Vision Laboratory
Retina Foundation of the Southwest
Dallas, Texas, US
Vice Chair for Clinical Practice, Wilmer Eye Institute
Johns Hopkins University
Baltimore, Maryland, US
Follow our latest developments.